about
Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Liver steatosis quantification using magnetic resonance imaging: a prospective comparative study with liver biopsy.Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.Ribavirin for chronic hepatitis E virus infection in transplant recipients.Assessment of biopsy-proven liver fibrosis by 2D-shear wave elastography: An individual patient data based meta-analysis.Populations at risk for alveolar echinococcosis, FrancePredictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in FranceClinical features and evolution of alveolar echinococcosis in France from 1982 to 2007: results of a survey in 387 patients.Sofosbuvir-based Regimens in HIV/HCV Coinfected Patients after Liver Transplantation: Results from the ANRS CO23 CUPILT Study.The role of angiogenesis in endocrine liver metastases: an experimental study.Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure.Construction of recombinant adenoviruses that produce infectious hepatitis B virus.Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.Age-dependent variations of human and rat colon myofibroblasts in culture: Influence on their functional interactions with colon cancer cells.Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.Recurrent alcoholic cirrhosis in severe alcoholic relapse after liver transplantation: a frequent and serious complication.Assessment of adrenal function in patients with acute hepatitis using serum free and total cortisol.Cardiovascular risk 10 years after liver transplant.Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.Skin cancers after liver transplantation: retrospective single-center study on 371 recipients.Endoscopic treatment of gastroesophageal varices in young infants with cyanoacrylate glue: a pilot study.Acute hepatitis C with evidence of heterosexual transmission: a new case.Immunosuppression in HCV-positive liver transplant recipients: Pandora's box?What is the best alternative to inulin clearance to estimate GFR in patients with decompensated alcoholic cirrhosis?Noninvasive diagnosis and prognosis of liver cirrhosis: a comparison of biological scores, elastometry, and metabolic liver function tests.Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil".Long-term treatment reduction and steroids withdrawal in children with autoimmune hepatitis: a single centre experience on 55 children.Sorafenib-induced bilateral osteonecrosis of femoral heads.Age-related variability of mycophenolate mofetil exposure in stable pediatric liver transplant recipients and influences of donor characteristics.Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study.Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.Atenolol hepatotoxicity: report of a complicated case.
P50
Q33426112-7AFD87F1-2FBD-47BB-96E0-10488CD7906DQ33509799-07C0DA27-EF3F-448D-93CB-25B628DEB73AQ34093754-BFD989E8-2974-40D4-8B06-595BB20243C8Q34410881-E79C8984-4624-416D-89FC-B0E70FD0CFA1Q36332475-1DC61B92-9268-41B4-A4E1-4B2618A6EA3AQ36825448-20CDFEA0-AE22-4CC8-818E-FAB9A8D763A6Q36875036-4413DFA6-47B8-4B36-994F-A108D40F4A6FQ37250436-94037D58-D3E5-4329-A4F6-9CE1BD8BBB64Q38440184-0C909367-99ED-4E54-B45B-0A4D1970AE36Q40068076-2B220ECB-EEA9-4338-A97A-E6A1EFB1D23FQ40104169-9693A32D-8D12-4564-9D91-AF9FE1D7AD36Q40476119-08A16F8A-E08B-4D56-9131-E6D6ABDA3739Q40592592-17411BC4-C007-4A2F-B75E-09E684D632B7Q40635393-E83EA414-5D9A-453D-8380-A9B9FAAADC50Q40645429-FC687F8D-D08F-4507-A8B0-BD9494E186A4Q40676713-C4B31ECC-8F11-46B3-AF5E-B3F72A1D64DAQ40868665-8C01E5D4-FE33-46B1-9E27-090D572F9D14Q41475691-C33E0EE4-9791-4FE2-96E1-9CCAB239756EQ41591012-F6DE4F95-0352-42FE-8CDA-B7CDDE1CC6C5Q41666894-FEE016EC-DF60-4AE9-9881-C1116DF368A8Q42240555-72F0CB1B-A62B-467C-AF57-944C1019FAEFQ42272968-46094A34-DB97-4A72-B6D4-A3FF98FDA899Q42455593-33688154-F63C-428E-BAE1-FF4C3E09CD74Q42609342-96B16CD7-53EA-4891-8494-0F2CB560ADBFQ42998360-894EA507-4594-420D-A708-F3F6A0BFACD7Q43041768-88E505DF-7D0C-40CB-9A34-AD2C22C28158Q43064211-A4258B78-2AD9-4AD1-8803-AC3A0C49B8D7Q43158469-A94A3F59-CFA4-454D-866E-47436B0C5B29Q43193965-708CD722-C8AC-40C9-A9B2-8941A937F39FQ43205304-C269B772-2A09-4811-86F4-3E84349CC63CQ43243993-204C6BAE-8E39-4F23-B4C3-0EE0C4DB8464Q43250047-B4D80612-ACA5-41DE-84BA-9454ACA8F2FBQ43250910-5631F78D-7444-4DBB-980D-E5B05C5A8983Q43251935-AC98F061-9924-4CB7-B496-BEB27A8D05B5Q43269347-C69C5135-D72E-4CEF-80FC-943B57C96722Q43272334-0405F135-CE13-424D-9332-1E68D3D7FC77
P50
description
onderzoeker
@nl
name
Jérôme Dumortier
@ast
Jérôme Dumortier
@en
Jérôme Dumortier
@nl
Jérôme Dumortier
@sl
type
label
Jérôme Dumortier
@ast
Jérôme Dumortier
@en
Jérôme Dumortier
@nl
Jérôme Dumortier
@sl
prefLabel
Jérôme Dumortier
@ast
Jérôme Dumortier
@en
Jérôme Dumortier
@nl
Jérôme Dumortier
@sl